In 93 children with AML, NHL or solid tumours on myelosuppressive chemotherapy, prophylactic romiplostim did not improve 3-week platelet recovery vs standard care (91.3% vs 88.1%; P=0.73). Secondary: grade ≥2 bleeding 0% vs 14%; no thrombotic events.
RCTn = 93
Bansal et al. Romiplostim for chemotherapy induced thrombocytopenia in pediatric cancers